

Stock Update

Strong performance, maintain Hold


GlaxoSmithKline Consumer Healthcare

Reco: Hold | CMP: Rs7,146


Company details

Price target:	Rs7,931
Market cap:	Rs30, 052 cr
52-week high/low:	Rs7,935/5,849
NSE volume: (No of shares)	29,893
BSE code:	500676
NSE code:	GSKCONS
Sharekhan code:	GSKCONS
Free float: (No of shares)	1.2 cr

Shareholding pattern



Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-0.7	-7.5	-1.3	21.8
Relative to Sensex	2.3	-9.9	-7.6	13.2

Key points

- Volume growth sustains; Low input cost and efficiencies led to margin expansion: GSK Consumer reported strong results in Q4FY2019, with broad-based growth across products and channels. Revenue grew by 9%, driven by 6.3% volume growth. Business auxiliary income rose by 20% y-o-y, led by double-digit growth across all products. Unlike other FMCG companies, GSK Consumers continued to see acceleration in the rural growth with double-digit revenue growth during the quarter. Gross margin expanded by 164BPS y-o-y, while operating profit margin (OPM) improved by 357 BPS y-o-y to 24.8% due to cost savings and operational efficiencies. Operating profit grew by 27.4% y-o-y to Rs. 318.5 crore. This along with higher other income led to reported PAT growing by 34.9% to Rs. 285.8 crore during the quarter. However, other income includes one-off exceptional gain of Rs. 46 crore towards tax reversal, excluding which adjusted PAT would have grown by 13% during the quarter.

- Company remains leader in the HFD category; Sachets continue to grow in double digits: In the health food drinks (HFD) category, Horlicks continues to be a leader with value-based market share standing at 42.9% (volume market share stood at 49.5%), while that of Boost stood at 10.7% (volume market share is 14%). The HFD category's revenue grew in high single digit with volume growth standing at ~6% during the quarter. Both Horlicks and Boost have grown in single digits. The recently launched Horlicks Protein+ is gaining market share sequentially and it currently holds 5-6% market share. Sachet sales (contributes 10% to overall revenue) grew in the upwards of 20%, driven by high double-digit volume growth (driving penetration into rural areas). Exports grew by 24%, with volume growth of 21% in Q4FY2019. Malaysia was another market that became part of GSK Consumers' export revenue during the quarter. Excluding Malaysia, export revenue grew by 67% on like-to-like basis. The company has expanded its distribution reach by 1,96,000 outlets this year across the portfolio (increased by 10% on a y-o-y basis).

- Volumes to grow by 5-7%; Rising input cost to put margin pressure in the near term: GSK Consumer's revenue grew by 12% in FY2019,

driven by 10% volume growth. Management has indicated slowdown in the demand environment with rural India's growth slowing down from the second half of Q4FY2019. We expect volume growth to sustain at 5-7% in FY2020 and gradually increase with improvement in domestic demand. Steady growth seen in base products, increasing rural penetration led by sachets, and growing acceptance and awareness of high science products such as *Horlicks Protein+* (Rs. 50crore revenue by FY2020), *Women's Horlicks* and *Horlicks Growth+* (Rs. 35 crore-40 crore revenue by FY2020) will be one of the key revenue drivers in the near to medium term. Restructuring of the foods business (~5% of total revenue) is done by exiting from loss-making products (revenue declined by 19% y-o-y in FY2019). Going ahead, management is expecting to add new products in the foods segment, which will help in achieving good growth in the coming years. Dairy prices have increased by 40% y-o-y and barley prices have increased by 30% y-o-y in recent months. So, to mitigate this input cost

inflation, the company has taken 2.5-3.0% price hike in January 2019. This along with efficient buying of key inputs will help the company to mitigate rising cost pressures to some extend in the coming quarters. Thus, we expect OPM to remain at about 23% in FY2020/FY2021.

- Maintain Hold with an unchanged PT of Rs. 7,931:** We have fine-tuned our earnings estimates for FY2020 and FY2021 to factor in better-than-expected operating performance. The merger of GSK Consumer with Hindustan Unilever Limited (HUL) is going as planned and is expected to fructify by the end of FY2020 with all required approvals likely in place. The business of GSK Consumer is growing steadily; and under HUL's umbrella, growth prospects of the brands will further improve in the near to medium term. We believe it is prudent for shareholders of GSK Consumer to hold the stock as the share-swap deal is more favourable towards shareholders of GSK Consumer. Hence, we maintain our Hold recommendation on the stock with an unchanged price target (PT) of Rs. 7,931.

Valuation (Standalone)

Particulars	FY2017	FY2018	FY2019E	FY2020E	FY2021E	Rs cr
Revenue (Rs crore)	4425.9	4377.1	4832.0	5428.8	6127.7	
OPM (%)	18.9%	20.2%	22.7%	22.9%	22.9%	
PAT (Rs crore)	656.7	700.1	885.8	993.2	1108.1	
EPS (Rs.)	156.1	166.5	210.6	236.1	263.5	
P/E (x)	45.6	42.8	33.8	30.2	27.0	
EV/EBIDTA (x)	24.9	23.1	18.9	16.9	14.8	
RONW (%)	22.2	21.2	23.8	23.5	23.2	
ROCE (%)	34.2	32.6	36.1	35.2	34.6	

Results (Standalone)

Particulars	Q4FY19	Q4FY18	yoy%	Q3FY19	qoq%
Total operating income	1286.1	1179.6	9.0	1116.8	15.2
Total Expenditure	967.6	929.6	4.1	878.3	10.2
Operating Profit	318.5	250.0	27.4	238.5	33.5
Other Income	76.9	84.2	-8.6	84.3	-8.7
EBIDTA	395.4	334.2	18.3	322.8	22.5
Interest	0.2	0.8	-74.0	0.2	-4.8
Depreciation	14.9	14.5	2.6	15.8	-5.6
PBT	380.3	318.9	19.2	306.8	24.0
Tax	140.4	107.1	31.2	125.7	11.7
Adjusted PAT	239.8	211.8	13.2	181.1	32.4
Extra ordinary item	46.0	-	-	40.0	15.0
Reported PAT	285.8	211.8	34.9	221.1	29.3
EPS (Rs.)	57.0	50.4	13.2	43.0	32.4
			BPS		BPS
GPM (%)	70.0	68.3	164BPS	70.7	-74BPS
OPM (%)	24.8	21.2	357BPS	21.4	341BPS

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. KanjurMarg Railway Station, KanjurMarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.